Ming‐Chih Hou

4.8k total citations · 1 hit paper
192 papers, 3.4k citations indexed

About

Ming‐Chih Hou is a scholar working on Hepatology, Epidemiology and Surgery. According to data from OpenAlex, Ming‐Chih Hou has authored 192 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 130 papers in Hepatology, 102 papers in Epidemiology and 55 papers in Surgery. Recurrent topics in Ming‐Chih Hou's work include Liver Disease Diagnosis and Treatment (91 papers), Liver Disease and Transplantation (81 papers) and Hepatocellular Carcinoma Treatment and Prognosis (52 papers). Ming‐Chih Hou is often cited by papers focused on Liver Disease Diagnosis and Treatment (91 papers), Liver Disease and Transplantation (81 papers) and Hepatocellular Carcinoma Treatment and Prognosis (52 papers). Ming‐Chih Hou collaborates with scholars based in Taiwan, United States and China. Ming‐Chih Hou's co-authors include Han‐Chieh Lin, Shou‐Dong Lee, Fa‐Yauh Lee, Yi‐Hsiang Huang, Full‐Young Chang, Chien‐Wei Su, Teh‐Ia Huo, I‐Cheng Lee, Pei‐Chang Lee and Jiing‐Chyuan Luo and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Hepatology.

In The Last Decade

Ming‐Chih Hou

171 papers receiving 3.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor–treated unresectable hepatocellular carcinoma

2022 132 citations Pei‐Chang Lee, Ya‐Wen Hung et al. profile →

Peers

Countries citing papers authored by Ming‐Chih Hou

Since Specialization

Citations

This map shows the geographic impact of Ming‐Chih Hou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ming‐Chih Hou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ming‐Chih Hou more than expected).

Fields of papers citing papers by Ming‐Chih Hou

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ming‐Chih Hou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ming‐Chih Hou. The network helps show where Ming‐Chih Hou may publish in the future.

Co-authorship network of co-authors of Ming‐Chih Hou

This figure shows the co-authorship network connecting the top 25 collaborators of Ming‐Chih Hou. A scholar is included among the top collaborators of Ming‐Chih Hou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ming‐Chih Hou. Ming‐Chih Hou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Targeting Lcn2 to Inhibit Myocardial Cell Ferroptosis is a Potential Therapy for Alleviating Septic Cardiomyopathy 2025 ·Inflammation ·Cheng Jiang, Ming‐Chih Hou, Shougang Sun, Gang Chen, Feng Bai, (unknown)	3
2	The influences of antihistamine on liver fibrosis, vasoresponsiveness, and portosystemic shunting in bile duct–ligated cirrhotic rats 2025 ·Journal of the Chinese Medical Association ·(unknown), Ching‐Chih Chang, Chiao‐Lin Chuang, Shao‐Jung Hsu, Ming‐Hung Tsai, Chia-Jui Tsai, (unknown), Ming‐Chih Hou, (unknown)	0
3	Triglyceride-glucose index and cancer risk: a prospective cohort study in Taiwan 2025 ·Diabetology & Metabolic Syndrome ·(unknown), (unknown), Chih-Jen Huang, Shiao‐Ya Hong, Hwai‐I Yang, Ying‐Ying Yang, Chia‐Chang Huang, (unknown), Tzu‐Hao Li, Chien‐Wei Su, Ming‐Chih Hou	1
4	Paracentesis exceeding three liters increases risks of acute kidney injury even in cirrhotic patients with albumin infused refractory ascites 2025 ·Journal of the Formosan Medical Association ·(unknown), Kuei‐Chuan Lee, (unknown), Yun‐Cheng Hsieh, Teh‐Ia Huo, Han-Chieh Lin, Ming‐Chih Hou	0
5	Sodium‐Glucose Cotransporter 2 Inhibitors Use in Patients With Liver Cirrhosis 2025 ·Diabetes/Metabolism Research and Reviews ·Fu‐Shun Yen, Ming‐Chih Hou, (unknown), Yuhan Huang, (unknown), (unknown), (unknown), Chii‐Min Hwu, Chih‐Cheng Hsu	0
6	Effects of glucagon-like peptide-1 receptor agonists on liver-related and cardiovascular mortality in patients with type 2 diabetes 2024 ·BMC Medicine ·Fu‐Shun Yen, Ming‐Chih Hou, James Cheng‐Chung Wei, (unknown), Chii‐Min Hwu, Chih‐Cheng Hsu	14
7	Hepatic Events During Immune Checkpoint Inhibitor Treatment Between Liver and Non‐Liver Malignancies in Hepatitis B Endemic Areas 2024 ·Alimentary Pharmacology & Therapeutics ·Yi‐Ping Hung, Pei‐Chang Lee, Yen‐Hwa Chang, Muh‐Hwa Yang, Chao‐Hua Chiu, Ming‐Huang Chen, Keng‐Hsin Lan, I‐Cheng Lee, Ming‐Chih Hou, Yee Chao, Yi‐Hsiang Huang	3
8	Fructooligosaccharides reverses hepatic vascular dysfunction and dysbiosis in rats with liver cirrhosis and portal hypertension 2024 ·European Journal of Clinical Investigation ·(unknown), Hui‐Chun Huang, Ching‐Chih Chang, Chiao‐Lin Chuang, Shao‐Jung Hsu, Ming‐Chih Hou, Fa‐Yauh Lee	1
9	The association between proton‐pump inhibitor use and recurrence of hepatocellular carcinoma after hepatectomy 2024 ·Journal of Gastroenterology and Hepatology ·(unknown), (unknown), Elise Chia‐Hui Tan, Wei‐Yu Kao, Pei‐Chang Lee, Yi‐Hsiang Huang, Teh‐Ia Huo, Ming‐Chih Hou, Jaw‐Ching Wu, Chien‐Wei Su	1
10	Prognostic Prediction for Patients with Hepatocellular Carcinoma and Ascites: Role of Albumin-Bilirubin (ALBI) Grade and Easy (EZ)-ALBI Grade 2023 ·Cancers ·(unknown), Shu‐Yein Ho, Po‐Hong Liu, (unknown), Yi‐Hsiang Huang, Chien‐Wei Su, Ming‐Chih Hou, Teh‐Ia Huo	7
11	Entecavir versus tenofovir on prognosis of hepatitis B virus‐related hepatocellular carcinoma after curative hepatectomy 2023 ·Alimentary Pharmacology & Therapeutics ·Wei‐Yu Kao, Elise Chia‐Hui Tan, Hsin‐Lun Lee, Yi‐Hsiang Huang, Teh‐Ia Huo, Chun‐Chao Chang, Jeng‐Fong Chiou, Ming‐Chih Hou, Jaw‐Ching Wu, Chien‐Wei Su	8
12	The outcomes and prognostic factors of patients with hepatocellular carcinoma and normal serum alpha fetoprotein levels 2022 ·Journal of the Formosan Medical Association ·(unknown), (unknown), Chi‐Jen Chu, Pei‐Chang Lee, Teh‐Ia Huo, Yi‐Hsiang Huang, Yee Chao, Ming‐Chih Hou, Jaw‐Ching Wu, Chien‐Wei Su	8
13	Dual hepatitis B and C-associated hepatocellular carcinoma: clinical characteristics, outcome, and prognostic role of albumin–bilirubin grade 2022 ·International Journal of Clinical Oncology ·(unknown), Shu‐Yein Ho, Po‐Hong Liu, (unknown), Cheng‐Yuan Hsia, Yi‐Hsiang Huang, Chien‐Wei Su, (unknown), Rheun‐Chuan Lee, Ming‐Chih Hou, Teh‐Ia Huo	6
14	Radiofrequency Ablation versus Transarterial Chemoembolization for Hepatocellular Carcinoma within Milan Criteria: Prognostic Role of Tumor Burden Score 2022 ·Cancers ·Shu‐Yein Ho, Po‐Hong Liu, (unknown), Yi‐Hsiang Huang, (unknown), Chien‐Wei Su, Ming‐Chih Hou, Teh‐Ia Huo	6
15	Determinants of Survival and Post-Progression Outcomes by Sorafenib–Regorafenib Sequencing for Unresectable Hepatocellular Carcinoma 2022 ·Cancers ·I‐Cheng Lee, Yee Chao, Pei‐Chang Lee, San‐Chi Chen, (unknown), (unknown), (unknown), Ming‐Chih Hou, Yi‐Hsiang Huang	8
16	Effect of Transarterial Chemoembolization on ALBI Grade in Intermediate-Stage Hepatocellular Carcinoma: Criteria for Unsuitable Cases Selection 2021 ·Cancers ·(unknown), I‐Cheng Lee, Rheun‐Chuan Lee, Ya‐Wen Hung, Chien‐Wei Su, Ming‐Chih Hou, Yee Chao, Yi‐Hsiang Huang	9
17	Easy albumin–bilirubin score as a new prognostic predictor in hepatocellular carcinoma 2021 ·Hepatology Research ·Shu‐Yein Ho, Po‐Hong Liu, Chia‐Yang Hsu, (unknown), Yi‐Hsiang Huang, Chien‐Wei Su, Cheng‐Yuan Hsia, Ping‐Hsing Tsai, Shih‐Jie Chou, Rheun‐Chuan Lee, Ming‐Chih Hou, Teh‐Ia Huo	16
18	Tumor burden score as a new prognostic marker for patients with hepatocellular carcinoma undergoing transarterial chemoembolization 2021 ·Journal of Gastroenterology and Hepatology ·Shu‐Yein Ho, Po‐Hong Liu, Chia‐Yang Hsu, (unknown), Yi‐Hsiang Huang, Chien‐Wei Su, Rheun‐Chuan Lee, Ping‐Hsing Tsai, Ming‐Chih Hou, Teh‐Ia Huo	29
19	Albumin‐bilirubin grade‐based nomogram of the BCLC system for personalized prognostic prediction in hepatocellular carcinoma 2019 ·Liver International ·Shu‐Yein Ho, (unknown), Po‐Hong Liu, Cheng‐Yuan Hsia, (unknown), Yi‐Hsiang Huang, (unknown), Chien‐Wei Su, Rheun‐Chuan Lee, Ming‐Chih Hou, Teh‐Ia Huo	24
20	Insulin reverses major portal hypertension-related derangements in rats with liver cirrhosis and diabetes 2018 ·Clinical Science ·I‐Fang Hsin, Hui‐Chun Huang, Ching-Chih Chang, Shao‐Jung Hsu, Fa‐Yauh Lee, Teh‐Ia Huo, Chiao‐Lin Chuang, Ming‐Chih Hou, Shou‐Dong Lee	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact